RxDoctor Payments Data

Sydney Pomenti, MD

Gastroenterology · New York, NYNPI 1306379680

Payments from drug & device makers

$1,756in general payments, 2019–2025

Across 61 payments — averaging $28.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$381
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$290
  • Sanofi$267
  • Aimmune Therapeutics, Inc.$145
  • Janssen Scientific Affairs, LLC$125
  • Gilead$84
  • plus $463 from 10 others

What the payments were for

  • Food & beverage$1,756100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,756 in reported general payments places this provider in the 45th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$59,108
Medicare patients
196
Services billed
473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbsrelaTenapanor Hcl29$66,431
LinzessLinaclotide87$59,422
VoqueznaVonoprazan Fumarate19$29,611
Aprepitant20$28,550
Omeprazole87$2,817
Pyridostigmine Bromide21$1,423
Esomeprazole Magnesium16$681
Mirtazapine22$413
Buspirone Hcl14$297
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg18$260
Famotidine11$195
Pantoprazole Sodium13$184
Ondansetron OdtOndansetron12$171
Nortriptyline Hcl13$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ardelyx, Inc.Ibsrela$81$66,43129 claims
AbbVieLinzess$381$59,42287 claims
Phathom Pharmaceuticals, Inc.Voquezna$23$29,61119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →